Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B

Journal of Gastroenterology

Volumn 49, Issue 3, 2014, Pages 470-480

  Tanaka, Mio ^a   Suzuki, Fumitaka ^a   Seko, Yuya ^a   Hara, Tasuku ^a   Kawamura, Yusuke ^a   Sezaki, Hitomi ^a   Hosaka, Tetsuya ^a   Akuta, Norio ^a   Kobayashi, Masahiro ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Adefovir dipivoxil; Fanconi's syndrome; Hepatitis B virus; Hypophosphatemia; Osteomalacia; Renal dysfunction

Indexed keywords

ADEFOVIR DIPIVOXIL; ALKALINE PHOSPHATASE; CALCITRIOL; CREATININE; ENTECAVIR; LAMIVUDINE; PHOSPHATE; URIC ACID; ADENINE; ANTIVIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOACIDURIA; ANKLE PAIN; ARTICLE; BONE PAIN; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; HYPOPHOSPHATEMIC RICKETS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FUNCTION; LONG TERM CARE; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MIDDLE AGED; NEPHROTOXICITY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; URIC ACID BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; DRUG COMBINATION; HEPATITIS B, CHRONIC; INCIDENCE; KIDNEY DISEASES; MULTIVARIATE ANALYSIS; RISK FACTOR; TIME;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; CREATININE; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS B, CHRONIC; HUMANS; HYPOPHOSPHATEMIA; INCIDENCE; KIDNEY DISEASES; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84897111702     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0779-0     Document Type: Article

References (42)

1. Lee WM, Hepatitis B. Virus infection. N Engl J Med. 1997;337:1733-45.
2. Dienstag JL, Hepatitis B. Virus infection. N Engl J Med. 2008;359:1486-500.
3. Lai C-L, Chien R-N, Leung NWY, Chang TT, Guan R, Tai D-I, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61-8. (Pubitemid 28304879)
4. Chen CH, Lee CM, Lu SN, Wang JH, Tung HD, Hung CH, et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol. 2004;41:454-61. (Pubitemid 39158755)
5. Suzuki F, Suzuki Y, Tsubota A, Akuta N, Someya T, Kobayashi M, et al. Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy. J Hepatol. 2002;37:824-30. (Pubitemid 35404222)
6. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, Hosaka T, et al. Efficacy of lamivudine therapy and factors associated with emergence ofresistance in chronic hepatitis B virus infection in Japan. Intervirology. 2003;46:182-9. (Pubitemid 36928649)
7. Hashimoto Y, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Clinical and virological effects of long-term (over 5 years) lamivudine therapy. J Med Virol. 2010;82:684-91.
8. Peters MG, Hann HH, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126:91-101. (Pubitemid 38040727)
9. Hosaka T, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Someya T, Sezaki H, Akuta N, Arase Y, Ikeda K, Kumada H. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol. 2007;42:368-74. (Pubitemid 47097253)
10. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007;45:307-13. (Pubitemid 46374587)
11. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res. 2010;40:1-7.
12. Izzedine H, Hulot JS, Launay-Vacher V, Marcellini P, Hadziyannis SJ, Currie G, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004;66:1153-8. (Pubitemid 39121022)
13. Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009;50:727-34.
14. Tamori A, Enomoto M, Kobayashi S, Iwai S, Morikawa H, Sakaguchi H, et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J Viral Hepat. 2010;17:123-9.
15. Kim YJ, Cho HC, Sinn DH, Gwak GY, Choi MS, Koh KC, et al. Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroenterol Hepatol. 2012;27:306-12.
16. Jung YK, Yeon JE, Choi JH, Kim CH, Jung ES, Kim JH, et al. Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient. Gut Liver. 2010;4:389-93.
17. Law ST, Li KK, Ho YY. Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil - is there a safe dose? J Clin Pharm Ther. 2012;37:128-31.
18. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis. 2003;41:292-309. (Pubitemid 36152447)
19. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides, Nucleotides Nucleic Acids. 2001;20:641-8. (Pubitemid 32821831)
20. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16. (Pubitemid 36245757)
21. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950;29:496-507.
22. Lewis WH, Alvey AS. Changes with age in the renal function in adult men. I. Clearance of urea. Am J Physiol. 1938;123:500-15.
23. Wollom GL, Gifford RW. The kidney as a target organ in hypertension. Geriatrics. 1976;31:71-9.
24. Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984;26:861-8. (Pubitemid 15197008)
25. Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008;4:444-52.
26. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361:1279-90.
27. Kahn J, Lagakos S, Wulfsohn M, Cherng D, Miller M, Cherrington J, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999;282:2305-12. (Pubitemid 30013061)
28. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673-81. (Pubitemid 41007822)
29. Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012;35:1317-25.
30. Amanzadeh J, Jr. Reilly RF. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol. 2006;2:136-48.
31. Bushinsky DA, Monk RD. Electrolyte quintet: calcium. Lancet. 1998;352:306-11.
32. Weisinger JR, Bellorín-Font E. Magnesium and phosphorus. Lancet. 1998;352:391-6. (Pubitemid 28352214)
33. Cirillo M, Ciacci C, De Santo NG. Age, renal tubular phosphate reabsorption, and serum phosphate levels in adults. N Engl J Med. 2008;359:864-6.
34. Izzedine H, Launay-Vacher V, Isnard-Bagnis C, Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis. 2003;41:292-309. (Pubitemid 36152447)
35. Kim DH, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab. 2012;14.
36. Carpenter TO. The expanding family of hypophosphatemic syndromes. J Bone Miner Metab. 2012;30:1-9.
37. Laing CM, Toye AM, Capasso G, Unwin RJ. Renal tubular acidosis: developments in our understanding of the molecular basis. Int J Biochem Cell Biol. 2005;37:1151-61. (Pubitemid 40381191)
38. Clarke BL, Wynne AG, Wilson DM, Fitzpatrick LA. Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features. Clin Endocrinol. 1995;43:479-90.
39. Wong T, Girgis CM, Ngu MC, Chen RC, Emmett L, Archer KA, et al. Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B. J Clin Endocrinol Metab. 2010;95:479-80.
40. Girgis CM, Wong T, Ngu MC, Emmett L, Archer KA, Chen RC, Seibel MJ. Hypophosphataemic osteomalacia in patients on adefovir dipivoxil. J Clin Gastroenterol. 2011;45:468-73.
41. Kim DH, Sung DH, Min YK. Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review. J Bone Miner Metab. 2012; Epub ahead of print.
42. Ozeki I, Karino Y, Akaike J, Kimura R, Arakawa T, Nakashima T, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Kanzo. 2011;52:102-11.